drugset / Trial / NCT04894266

An Open-Label Study of Apabetalone in Covid Infection

NCT04894266

Phase 2/3 Terminated 1 enrolled Resverlogix Corp
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

Timeline

Start
2022-01-14
Primary completion
2022-06-22
Completion
2022-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Apabetalone Small molecule 100 mg

Indications